Full Text View
Tabular View
No Study Results Posted
Related Studies
Hyaluronan Versus NaCl 20 Ml Versus Placebo in Knee Osteoarthritis
This study is ongoing, but not recruiting participants.
Study NCT00144820   Information provided by Glostrup University Hospital,Copenhagen
First Received: September 2, 2005   No Changes Posted

September 2, 2005
September 2, 2005
May 1999
 
  • Pain measured on a visual scale on movement (VAS-movement)
  • At rest (VAS-rest)
  • During the night (VAS-night)
Same as current
No Changes Posted
  • KOOS scores (knee injury and osteoarthritis outcome score)
  • Daily consumption of analgetics
  • Cartilage and bone degradation markers
  • The quadriceps circumference (cm), ability to bend (degrees flexion) and stretch (degrees extension) the knee joint
  • Global assessment patient
  • Global assessment investigator
Same as current
 
Hyaluronan Versus NaCl 20 Ml Versus Placebo in Knee Osteoarthritis
Intra-Articular Injections of Hyaluronan Versus 20 Ml NaCl Versus Placebo in Treatment of Knee Osteoarthritis: a Randomised, Double-Blind, Placebo Controlled Single Centre Trial.

251 consecutive patients with knee arthrosis were randomized to one of three interventions: Four weekly injections of 2 ml isotonic saline (placebo), 2 ml sodium hyaluronate (hyaluronan) or 20 ml isotonic saline (excessive saline).

They all suffered from clinically and radiologically verified arthrosis of the knee with daily pain that did not respond to treatment with analgetics.

Results were evaluated at weeks 1,2,3,4,8,12,16 and 26. Biochemical markers for bone and cartilage degradation were measured in urine/blood.

 
Phase IV
Interventional
Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Osteoarthritis, Knee
Drug: Injection of Hyaluronan or Saline
 
Lundsgaard C, Dufour N, Fallentin E, Winkel P, Gluud C. Intra-articular sodium hyaluronate 2 mL versus physiological saline 20 mL versus physiological saline 2 mL for painful knee osteoarthritis: a randomized clinical trial. Scand J Rheumatol. 2008 Mar-Apr;37(2):142-50.

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Active, not recruiting
251
November 2001
 

Inclusion Criteria:

  • Patients, men/women age > 60 years with clinical,
  • Radiological and possible arthroscopical verified knee osteoarthritis.
  • Knee pain on the day of examination scoring more than 20 mm on a visual analogue scale (VAS) at baseline.

Exclusion Criteria:

  • Age below 60
  • Unconsciousness
  • Psychosis
  • Demens
  • Ingestion of drugs that may influence the results of the clinical examinations
  • Inflammatory diseases of the joints
  • Rheumatoid arthritis or other inflammatory arthritis as diagnosed by American College of Rheumatology criteria
  • Contraindication to hyalgan treatment
  • Previous intraarticular fracture of a knee joint
  • Infection or skin disease located at the place of injection and invasive procedures done to the knee joint within previous two months inclusive intra-articular injections of steroids.
  • Any other condition that might interfere with the efficacy assessment or completion of the trial.
Both
60 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Denmark
 
NCT00144820
 
KA 99005gs
Glostrup University Hospital,Copenhagen
 
Principal Investigator: Charlotte Lundsgaard, MD Copenhagen Trial Unit (CTU)
Glostrup University Hospital,Copenhagen
August 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP